Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA VII Commitment Letter Outlines Real-Time Review Expansion, Hiring Goals

Executive Summary

Allergenic extract products, previously excluded, also will become part of the user fee program beginning in FY 2023.

You may also be interested in...



US FDA’s Gene Therapy Office Poaches OCE’s Fashoyin-Aje For Oncology Position

Lola Fashoyin-Aje, formerly associate director of the Oncology Center of Excellence, will become director of the CBER Office of Therapeutic Products’ Office of Clinical Evaluation.

US FDA’s START Program Might See Expanded Funding If Pilot Meets Speed Goals

The program bringing Operation Warp Speed-like treatment to rare disease product development could expand if successful, but will require more employees and thus funding commitments from Congress and industry, CBER Director Peter Marks said.

US FDA Chief Of Staff Returning To CBER For Deputy Director Role

Julie Tierney will become CBER’s deputy director for strategy, policy and legislation, a newly created position.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel